E7777
Dr Reddy’s Lab inks agreement with Citius to sell anti-cancer agent E7777
Hyderabad/UNI: Pharma major Dr. Reddy’s Laboratories on Saturday announced that it has entered into a definitive agreement with Citius Pharmaceuticals to sell its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets.
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Company Limited.
Under the terms of the agreement, Dr. Reddy’s will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $ 40 million related to the CTCL (Cutaneous T-Cell Lymphoma) indication approval and up to $70 million for additional indication approvals.
The Hyderabad based pharma enterprise will receive certain sales-based milestones and tiered earn-out payments.
Erez Israeli, CEO, Dr. Reddy’s Laboratories said, "E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers."
"Post acquiring from Eisai, significant progress was made on the CTCL development front. We are confident of Citius’ ability to realize the full potential of E7777 in the treatment of CTCL as well as in their ability to develop this promising drug for additional oncology and immuno-oncology indications," he said.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
